Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Treatment of Anemia in Subjects With Non-Myeloid Malignancy Receiving Multicycle Chemotherapy
Phase 3
Completed
- Conditions
- AnemiaNon-Myeloid Malignancies
- Interventions
- Drug: Placebo
- First Posted Date
- 2005-05-17
- Last Posted Date
- 2010-01-15
- Lead Sponsor
- Amgen
- Target Recruit Count
- 391
- Registration Number
- NCT00110955
Treatment for Patients With Osteoarthritis (OA)
Phase 2
Completed
- Conditions
- Osteoarthritis
- Interventions
- Drug: Systemic AMG 108Other: Placebo
- First Posted Date
- 2005-05-17
- Last Posted Date
- 2008-06-23
- Lead Sponsor
- Amgen
- Target Recruit Count
- 160
- Registration Number
- NCT00110942
Treatment for Patients With Secondary Hyperparathyroidism of End-Stage Renal Disease (ESRD)
Phase 2
Completed
- Conditions
- End Stage Renal Disease
- First Posted Date
- 2005-05-17
- Last Posted Date
- 2010-04-23
- Lead Sponsor
- Amgen
- Target Recruit Count
- 850
- Registration Number
- NCT00110929
Utilization of Narrow Band Ultraviolet B (UVB) Light Therapy and Etanercept for the Treatment of Psoriasis
- First Posted Date
- 2005-05-17
- Last Posted Date
- 2013-05-24
- Lead Sponsor
- Amgen
- Target Recruit Count
- 86
- Registration Number
- NCT00110981
Treatment for Subjects With Active Rheumatoid Arthritis (RA)
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2005-05-17
- Last Posted Date
- 2013-04-26
- Lead Sponsor
- Amgen
- Registration Number
- NCT00110903
Study To Evaluate the Status of Subjects That Discontinued Participation in a Qualifying Amgen Sponsored AMG 073 Study Due to Kidney Transplantation
Completed
- Conditions
- Kidney Transplantation
- Interventions
- Other: Observations
- First Posted Date
- 2005-05-13
- Last Posted Date
- 2011-01-21
- Lead Sponsor
- Amgen
- Target Recruit Count
- 38
- Registration Number
- NCT00110656
Study of AMG 162 in Subjects With Advanced Cancer Currently Being Treated With Intravenous (IV) Bisphosphonates
Phase 2
Completed
- Conditions
- Bone Metastases in Men With Hormone-Refractory Prostate CancerBone Metastases in Subjects With Advanced Breast CancerBone Metastases in Subjects With Advanced Cancer or Multiple Myeloma
- Interventions
- Drug: IV Bisphosphonate q 4 weeksGenetic: AMG 162 180 mg (SC) q 12 weeksGenetic: AMG 162- 180 mg q 4 weeks
- First Posted Date
- 2005-03-04
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- Amgen
- Target Recruit Count
- 111
- Registration Number
- NCT00104650
Safety and Activity Study of an Oral Medication to Treat Moderate to Severe Crohn's Disease
Phase 2
Completed
- Conditions
- Crohn Disease
- First Posted Date
- 2005-02-07
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Amgen
- Target Recruit Count
- 70
- Registration Number
- NCT00102921
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Rocky Mountain Clincal Research, Golden, Colorado, United States
🇺🇸Arapahoe Gastroenterology, Littleton, Colorado, United States
Study Evaluating AMG 386 in Adult Patients With Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Tumors
- First Posted Date
- 2005-02-04
- Last Posted Date
- 2010-08-20
- Lead Sponsor
- Amgen
- Registration Number
- NCT00102830
AMG 531 Treatment of Thrombocytopenic Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP) Prior to Splenectomy
Phase 3
Completed
- Conditions
- Idiopathic Thrombocytopenic PurpuraThrombocytopenia
- Interventions
- Drug: PlaceboBiological: AMG 531
- First Posted Date
- 2005-01-28
- Last Posted Date
- 2022-11-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 62
- Registration Number
- NCT00102336
© Copyright 2025. All Rights Reserved by MedPath